For pediatric patients with CF, aminoglycosides are a critical component of antipseudomonal therapy for the treatment of lung infections (9), but treating such infections is becoming challenging due to intrinsic resistance conferred by MexXY-OprM (16, 17). Here, OPRM1 is linked to infection.